TipRanks
Advertisement
Advertisement
Takeda announces FDA acceptance of zasocitinib under priority review
PremiumThe FlyTakeda announces FDA acceptance of zasocitinib under priority review
24d ago
Takeda’s Zasocitinib Wins FDA Priority Review in Bid to Redefine Oral Psoriasis Care
Premium
Company Announcements
Takeda’s Zasocitinib Wins FDA Priority Review in Bid to Redefine Oral Psoriasis Care
24d ago
Takeda announces publication of data from Phase 3 studies of oveporexton
Premium
The Fly
Takeda announces publication of data from Phase 3 studies of oveporexton
29d ago
Bayer, Takeda expected to announce new pricing deals with White House, FT says
PremiumThe FlyBayer, Takeda expected to announce new pricing deals with White House, FT says
1M ago
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
Premium
The Fly
Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright
1M ago
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
Premium
The Fly
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
1M ago
Analyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
PremiumRatingsAnalyst Raises Price Target to ¥6,800 and Reiterates Buy on Strong Drug Performance, Pipeline Upside, and Long-Term Growth Drivers
2M ago
Takeda award from Veterans Affairs posted to SAM.gov site
Premium
The Fly
Takeda award from Veterans Affairs posted to SAM.gov site
2M ago
Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1
Premium
Company Announcements
Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―